{"title":"消失性纵隔肿块与信使核糖核酸严重急性呼吸系统综合征冠状病毒2型疫苗接种相关:一例罕见病例报告","authors":"T. Kosaka, S. Nakazawa, T. Ibe, K. Shirabe","doi":"10.21037/amj-22-13","DOIUrl":null,"url":null,"abstract":"Background: Thymic hyperplasia has occasionally been reported as an immune response to vaccination for severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). We herein report a rare case of a vanishing mediastinal mass associated with mRNA SARS-CoV-2 vaccination. Case Description: A woman in her forties presented with continuous fever after receiving her first mRNA-1273 SARS-CoV-2 vaccination. Chest computed tomography (CT) examination revealed an anterior mediastinal mass of 66-mm in diameter. She was referred to our hospital for evaluation of the anterior mediastinal mass.18F-fluorodeoxyglucose positron emission tomography (FDG-PET) revealed markedly increased uptake in the mediastinal mass. The differential diagnosis included thymoma, thymic cancer, and lymphoma. Although a CT scan performed 25 days after vaccination showed that the mediastinal mass had shrunk to 32 mm, the lesion was still present and a needle biopsy was performed. Unfortunately, accurate pathological examination could not be achieved because of small specimen. A surgical biopsy by the thoracoscopic approach was next planned to rule out malignancy. However, a CT scan prior to surgical biopsy performed 2 months after vaccination revealed that the mediastinal mass had completely disappeared. The surgical biopsy was cancelled. Because there was no residual lesion at 6 months, we concluded that the mediastinal mass was an adverse effect of the SARS-CoV-2 vaccination, presenting as a transient hyperplasia of the thymus. Conclusions: It is important to distinguish an immune response from a malignancy to avoid unnecessary surgery or treatment. Our case warns us that we should take into account the timing of SARS-CoV2 vaccination when we encounter a patient with mediastinal mass. © AME Medical Journal. All rights reserved.","PeriodicalId":72157,"journal":{"name":"AME medical journal","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Vanishing mediastinal mass associated with mRNA SARS-CoV-2 vaccination: a rare case report\",\"authors\":\"T. Kosaka, S. Nakazawa, T. Ibe, K. Shirabe\",\"doi\":\"10.21037/amj-22-13\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Thymic hyperplasia has occasionally been reported as an immune response to vaccination for severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). We herein report a rare case of a vanishing mediastinal mass associated with mRNA SARS-CoV-2 vaccination. Case Description: A woman in her forties presented with continuous fever after receiving her first mRNA-1273 SARS-CoV-2 vaccination. Chest computed tomography (CT) examination revealed an anterior mediastinal mass of 66-mm in diameter. She was referred to our hospital for evaluation of the anterior mediastinal mass.18F-fluorodeoxyglucose positron emission tomography (FDG-PET) revealed markedly increased uptake in the mediastinal mass. The differential diagnosis included thymoma, thymic cancer, and lymphoma. Although a CT scan performed 25 days after vaccination showed that the mediastinal mass had shrunk to 32 mm, the lesion was still present and a needle biopsy was performed. Unfortunately, accurate pathological examination could not be achieved because of small specimen. A surgical biopsy by the thoracoscopic approach was next planned to rule out malignancy. However, a CT scan prior to surgical biopsy performed 2 months after vaccination revealed that the mediastinal mass had completely disappeared. The surgical biopsy was cancelled. Because there was no residual lesion at 6 months, we concluded that the mediastinal mass was an adverse effect of the SARS-CoV-2 vaccination, presenting as a transient hyperplasia of the thymus. Conclusions: It is important to distinguish an immune response from a malignancy to avoid unnecessary surgery or treatment. Our case warns us that we should take into account the timing of SARS-CoV2 vaccination when we encounter a patient with mediastinal mass. © AME Medical Journal. All rights reserved.\",\"PeriodicalId\":72157,\"journal\":{\"name\":\"AME medical journal\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"AME medical journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21037/amj-22-13\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"AME medical journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21037/amj-22-13","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Vanishing mediastinal mass associated with mRNA SARS-CoV-2 vaccination: a rare case report
Background: Thymic hyperplasia has occasionally been reported as an immune response to vaccination for severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). We herein report a rare case of a vanishing mediastinal mass associated with mRNA SARS-CoV-2 vaccination. Case Description: A woman in her forties presented with continuous fever after receiving her first mRNA-1273 SARS-CoV-2 vaccination. Chest computed tomography (CT) examination revealed an anterior mediastinal mass of 66-mm in diameter. She was referred to our hospital for evaluation of the anterior mediastinal mass.18F-fluorodeoxyglucose positron emission tomography (FDG-PET) revealed markedly increased uptake in the mediastinal mass. The differential diagnosis included thymoma, thymic cancer, and lymphoma. Although a CT scan performed 25 days after vaccination showed that the mediastinal mass had shrunk to 32 mm, the lesion was still present and a needle biopsy was performed. Unfortunately, accurate pathological examination could not be achieved because of small specimen. A surgical biopsy by the thoracoscopic approach was next planned to rule out malignancy. However, a CT scan prior to surgical biopsy performed 2 months after vaccination revealed that the mediastinal mass had completely disappeared. The surgical biopsy was cancelled. Because there was no residual lesion at 6 months, we concluded that the mediastinal mass was an adverse effect of the SARS-CoV-2 vaccination, presenting as a transient hyperplasia of the thymus. Conclusions: It is important to distinguish an immune response from a malignancy to avoid unnecessary surgery or treatment. Our case warns us that we should take into account the timing of SARS-CoV2 vaccination when we encounter a patient with mediastinal mass. © AME Medical Journal. All rights reserved.